etodolac and cyclin d1

etodolac has been researched along with cyclin d1 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agus, DB; Carson, DA; Corr, M; Fox, W; Hedvat, M; Holden, S; Huang, G; Jain, A; Leoni, LM; Lu, D	1
Anderson, KC; Chauhan, D; Elliott, G; Hamasaki, M; Hideshima, T; Ishitsuka, K; Kanekal, S; Kumar, S; Leoni, LM; Munshi, NC; Podar, K; Raje, N; Roccaro, AM; Shiraishi, N; Tai, YT; Tassone, P; Yasui, H	1
Blair, SL; Carson, DA; Crain, B; Kato, S; Messer, K; Parker, BA; Pu, M; Schwab, RB; Wallace, AM; Weidner, N	1

Trials

1 trial(s) available for etodolac and cyclin d1

Article	Year
A window-of-opportunity biomarker study of etodolac in resectable breast cancer. Cancer medicine, 2015, Volume: 4, Issue:10 Topics: Administration, Oral; Aged; beta Catenin; Biomarkers, Tumor; Breast Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Gene Expression; Humans; Middle Aged; Preoperative Period; Retinoid X Receptor alpha	2015

Other Studies

2 other study(ies) available for etodolac and cyclin d1

Article	Year
Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer cell, 2004, Volume: 5, Issue:6 Topics: Animals; Antineoplastic Agents; Azo Compounds; Blotting, Western; CD36 Antigens; Cell Line; Cell Line, Tumor; Coloring Agents; Cyclin D1; Down-Regulation; Enzyme Activation; ErbB Receptors; Etodolac; Flow Cytometry; Humans; Lipid Metabolism; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Biological; Models, Chemical; Monocytes; Neoplasm Transplantation; NIH 3T3 Cells; Prostatic Neoplasms; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transcription Factors; Transcriptional Activation; Transfection	2004
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood, 2005, Jul-15, Volume: 106, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Caspases; Cell Adhesion; Cell Line, Tumor; Cyclin D1; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Etodolac; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Stereoisomerism	2005

Article

Year

Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma.

Cancer cell, 2004, Volume: 5, Issue:6

Topics: Animals; Antineoplastic Agents; Azo Compounds; Blotting, Western; CD36 Antigens; Cell Line; Cell Line, Tumor; Coloring Agents; Cyclin D1; Down-Regulation; Enzyme Activation; ErbB Receptors; Etodolac; Flow Cytometry; Humans; Lipid Metabolism; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Biological; Models, Chemical; Monocytes; Neoplasm Transplantation; NIH 3T3 Cells; Prostatic Neoplasms; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transcription Factors; Transcriptional Activation; Transfection

2004

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

Blood, 2005, Jul-15, Volume: 106, Issue:2

Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Caspases; Cell Adhesion; Cell Line, Tumor; Cyclin D1; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Etodolac; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Stereoisomerism

2005